Department of Cardiology, Aarhus University Hospital Skejby, Brendstrupgaardsvej 100,Aarhus, Denmark.
J Cardiovasc Med (Hagerstown). 2011 Dec;12(12):856-9. doi: 10.2459/JCM.0b013e32834da583.
Early revascularization with primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI) has been shown to reduce mortality, rates of nonfatal reinfarction and stroke, as compared to previous standard of care with thrombolytic therapy. Despite substantial evidence of its effectiveness, the use of PPCI varies considerably across Europe. The Stent for Life Initiative supports implementation of local STEMI treatment guidelines, helps to identify specific barriers to implementation of guidelines and defines actions to make sure that the majority of STEMI patients have access to PPCI. Launching a successful programme for PPCI requires the commitment and collaboration of a broad variety of members of the healthcare system. This narrative review is intended to describe some of the progress already seen in the 10 countries currently included in the Stent for Life Initiative and to report and discuss the engagement of the various stakeholders involved.
与之前的溶栓治疗标准相比，ST 段抬高型心肌梗死（STEMI）患者的早期经皮冠状动脉介入治疗（PPCI）已被证明可降低死亡率、非致死性再梗死和中风的发生率。尽管有大量证据表明其有效性，但 PPCI 在整个欧洲的使用情况差异很大。“生命之支架倡议”支持实施当地的 STEMI 治疗指南，帮助确定实施指南的具体障碍，并确定采取行动确保大多数 STEMI 患者能够获得 PPCI。要成功推出 PPCI 计划，需要医疗保健系统的各种成员的承诺和合作。本叙述性评论旨在描述目前在“生命之支架倡议”中包含的 10 个国家中已经看到的一些进展，并报告和讨论所涉及的各种利益相关者的参与情况。
